MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Steven M. Chaouki reported a compensation-related grant of stock options. He received options covering 26,982 shares of common stock at an exercise price of $1.44 per share, granted on June 30, 2026 under the company’s 2021 Equity Incentive Plan.

The options vest 100% on the grant date and are exercisable beginning that date, with an expiration date of June 30, 2036. Following this grant, Chaouki holds 26,982 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CHAOUKI STEVEN M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	26,982	$0.00	--

Holdings After Transaction: Stock Options — 26,982 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 26,982 options Underlying shares: 26,982 shares Exercise price: $1.44 per share +3 more

6 metrics

Stock options granted 26,982 options Grant to director Steven M. Chaouki on June 30, 2026

Underlying shares 26,982 shares Common stock underlying the granted options

Exercise price $1.44 per share Strike price for the granted stock options

Expiration date June 30, 2036 Option term end for this grant

Price at grant $0.00 per option No cash paid by director to receive the option award

Post-grant derivative holdings 26,982 options Total stock options held by the director after this grant

Key Terms

Stock Options, 2021 Equity Incentive Plan, exercise price, expiration date

4 terms

Stock Options financial

"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares..."

exercise price financial

"Stock options have a conversion or exercise price of 1.4400 per underlying share of common stock."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The options carry an expiration date of June 30, 2036 if not exercised earlier."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:17 PM Accepted by SEC EDGAR 07/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHAOUKI STEVEN M

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.44	06/30/2026		A		26,982		06/30/2026(1)	06/30/2036	Common Stock	26,982	$0	26,982	D

Explanation of Responses:

1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Steven M. Chaouki	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MAIA (MAIA) director Steven Chaouki report in this Form 4?

Steven M. Chaouki reported receiving a grant of stock options for 26,982 underlying shares of MAIA common stock. The award is compensation-related, not an open-market trade, and reflects additional equity-based incentives tied to the company’s 2021 Equity Incentive Plan.

How many MAIA (MAIA) shares are covered by the new stock options?

The granted stock options cover 26,982 shares of MAIA common stock. These options give the director the right to purchase that number of shares at a fixed exercise price, subject to the vesting and expiration terms disclosed in the filing and footnote.

What is the exercise price of Steven Chaouki’s MAIA stock options?

The exercise price of the stock options is $1.44 per share. This means Chaouki can purchase MAIA common shares at $1.44 once he exercises the options, provided he does so before they expire and in accordance with the plan’s terms.

When do Steven Chaouki’s MAIA stock options vest and become exercisable?

The options vest 100% on the June 30, 2026 grant date and are exercisable beginning as of that date. This immediate vesting structure allows the director to exercise the options any time after grant, up until their disclosed expiration date in 2036.

When do the newly granted MAIA stock options to Steven Chaouki expire?

The stock options expire on June 30, 2036, giving a 10-year term from the grant date. After that expiration date, any unexercised portion of the award lapses, and the director can no longer purchase MAIA shares under this specific option grant.

Under which plan were Steven Chaouki’s MAIA options granted?

The options were granted pursuant to MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan. This plan governs how equity awards like stock options are issued, including terms such as vesting, exercisability, and expiration for company directors and other eligible participants.